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by the health-related quality-of-life measures. Conversely, a patient with severe claudication
would not require treatment if his or her quality of life is not affected by the disease. Success of
an intervention is defined as improvement of at least one category and should be considered for
each of the outcomes measures. If more than one attribute is measured for a particular outcome
measure, improvement should be defined as an upward shift of at least one category 011 at least
half of the attributes, for example, at least two attributes on the WIQ and at least four attributes
on the 5F-36/RAND-36 (see Critical Issue 5, p 575).
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B4
B 4.1
B 4.1.1
Treatment of Intermittent Claudication
Overall Strategy and Basic Treatment for Intermittent Claudication
Overall Strategy
The overriding issue in the management of patients presenting with IC is that they are at signifi-
cant risk of developing severe and often fatal cardiovascular complications; thus, their most serious
problem is not the limitation of walking, even though that may be their only symptom. Patients
with IC are at 2 to 4 times greater risk of dying from the complications of generalized atheroscle-
rosis than similar people without claudication (see A 2.5.2, Cause of Death in Claudicants, p 519).
Therefore, the first priority in designing a treatment plan for these patients is to try to modify the
known risk factors for the progression of atherosclerosis and development of atherothrombotic
complications. It is important to explain to the patient the rationale for this strategy and that it is
not designed to improve the claudication distance. Emphasis should be put on those risk factors
whose modification has been shown to be particularly effectivein decreasing morbidity and mor-
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tality, for instance, cigarette smoking. Advice regarding this, as well as some other risks such as
obesity,has to be regularly reinforced. Modification of risk factors should be accompanied by the
long-term prescription of antiplatelet pharmacotherapy, usually low-dose aspirin.
The second step in the basic management in the newly diagnosed claudicant is the reassurance
of the patient that walking into his or her claudication pain not only does no harm, but is in fact
likely to gradually increase his or her pain-free walking distance. Regular walking exercise is like-
ly to be beneficial both for the leg and for the underlying general disease, through a number of
mechanisms. Risk factor modification, antiplatelet therapy, and regular exercise training are all
the treatment that most patients with IC will need and is all that most should be offered in the
current state of our knowledge. However, the condition of a minority of claudicants will deteri-
orate, and their handicap will become sufficiently severe to consider some local intervention,
angioplasty or surgery, for their PAD. On rare occasions, a patient's handicap may be so severe
at presentation that intervention may be considered even before a full trial of basie noninterven-
tional therapy. The decision to image the precise anatomy of the lesion depends on the decision
regarding whether some form of intervention would be recommended if the morphology of the
atherosclerotic lesion showed it suitable for intervention.
The decision to consider a patient for interventional therapy is arrived at by the patient balanc-
ing existing disability against the procedural risk and likelihood of long-term success of an inter-
vention. The patient's disability should be assessed in terms of not only claudication distance
but also the patient's job and preferred everyday activities. Thus, for instance, intervention may
be contemplated even in a long-distance claudicant, say, 500 meters on the flat, if this prevents a
patient from pursuing his or her normal occupation in the building trade. At the other extreme,
a short claudication distance might be accepted in an elderly retired person who has no particu-
lar desire to leave his of her home. On the other side of the equation is the risk of imaging and
then the risk of intervention. Even if imaging is by traditional angiography, the risk is very low.
In a multicenter trial of 118,591 arteriographic procedures reported by Hessel et al.! for exam-
ple, the incidences of complications with axillary, translumbar, and femoral approaches were
3.29%,2.89%, and 1.73% respectively; overall mortality rate was 0.025%. (See B 2.2.3, Imaging
Techniques, p 570.)
The risks of the actual intervention have also been significantly lowered by the advent of angio-
plasty (PTA). Complications of PTA today are for dle most part minor and typically do not
require surgical treatment. 2 Access-related complications range from less serious and more
common (eg, groin hematoma) to the serious but rare events (eg, retroperitoneal hematoma).3
The incidence of complications at the angioplasty site, 1% to 7% in most series, is similar to that
for percutaneous transluminal coronary angioplasty (PTCA) and consists principally of acute
occlusion. Many of these can be managed with lytic or adjunctive mechanical therapy, including
stents, so that in expert hands the need for emergency surgery because of a jeopardized limb is
rare.
The total incidence of complications countrywide is unknown, but it is probably higher than
that reported from specialized centers. Distal embolization has been reported in up to 5% of
cases." Most, however, are clinically silent,2 and even those that might be potentially problemat-
ic often can be treated successfully post-PTA by judicious usc of lytic therapy. Although these
complications are relatively minor, they and the significant recurrence rate after PTA must be
kept in mind, and there are several randomized trials, the most recent also employing quality-of-
life measures, that show no advantage of PTA over exercise training with extended follow-up
(see B 4.5, Comparison of Therapeutic Options, p 5117).
Both the risks and cost of percutaneous revascularization increase with the complexity and
extent of anatomic involvement. The decision to revascularize the patient with claudication
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therefore must take into account both symptoms and the results of noninvasive testing (see B 2,
Evaluation, p 556). Once having clarified the anatomic basis for claudication, the recommenda-
tion to advise percutaneous revascularization is then individualized according to the two consid-
erations just indicated. Diagnostic angiography may suggest that percutaneous revascularization
has a high likelihood of technical success in one patient, suggesting that he or she may be a suit-
able candidate for the procedure. In other patients, certain risks and a complex of anatomic fac-
tors suggesting a low likelihood of acute or long-term success may dictate that only surgical
revascularization would constitute effective therapy. In such a case, it may be appropriate to
defer the risk of surgery until the patient is more severely disabled. Imaging thus may critically
raise or lower the threshold for recommending that an intervention be performed.
Should the patient treated by percutaneous revascularization return with clinical evidence of
restenosis, repeat percutaneous intervention is probably indicated for the same reasons that led
to the recommendation for the original procedure. A certain proportion of these patients-as
had been clearly documented in certain patients undergoing one or more repeat coronary
angioplasty proceduress-s-c-will achieve a satisfactory long-term result after the second interven-
tion. If the imaging indicates primary or recurrent lesions unsuitable for safe angioplasty, the
possibility of surgical reconstruction has to be considered. The risks of this are significantly
greater than the risks of angioplasty, in terms of not only mortality but major morbidity and
delay in return to normal activities. Therefore, the assessment of the patient's general condition
becomes more central to deciding whether surgery is warranted.
Adopting this approach with maximum concern for safety and efficacyrequires coordinated input
from experts in angiology, cardiology, radiology, and vascular surgery. Guidelines for appropriate-
ness of intervention should be laid down by a team of involved specialists, but then individual
patient management can be based on the guidelines as interpreted by one or two members of the
team. Many centers currently perform an angiogram and then proceed immediately with percuta-
neous revascularization if needed. Other centers prefer to separate the diagnostic imaging from
the interventional procedure. These decisions require experienced judgment, and expert advice
from appropriate specialists on specific aspects should be obtained as needed.
Recommendation 21: Indications for i.nvasive therapy in intermittent claudication
Before offering a patient with intermittent claudication the option of any invasive ther-
apy, endovascular or surgical, the following considerations must be taken into account:
• A predicted or observed lack of adequate response to exercise therapy and risk factor
modification
• The patient must have a severe disability, either being unable to perform normal
work or having very serious impairment of other activities important to the patient
• Absence of other disease that would limit exercise even if the claudication was
improved (eg, angina or chronic respiratory disease)
• The individual's anticipated natural history and prognosis
• The morphology of the lesion must be such that the appropriate intervention would
have low risk and high probability of initial and long-term success
Critical Issue 6: Identifying patients with intermittent claudication at higher risk of
progression of peripheral arterial disease
There is a need for identification of the small group of patients with intermittent clau-
dication who, based on severity of symptoms, ankle:brachial pressure index, or anatomy
of the arterial lesion, or the presence of specific risk factors, are at higher risk of pro-
gression of peripheral arterial disease.
Pharmacotherapy aimed at increasing claudication distance and improving functional status is under
development (see B 4.2, Pharmacotherapy for Symptoms ofIntermittent Claudication, p 589).
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Other therapies designed to stimulate angiogenesis, improve skeletal muscle metabolism, and
modulate platelet and vascular endothelial function are all under development to treat the symp-
toms of claudication.
B 4.1.2 Basic Treatment
Risk factor modification
Modifiable atherosclerotic risk factors for PAD include smoking, diabetes mellitus, obesity,
hyperlipidemia, hypertension, and homocysteine elevation. These will be considered in approxi-
mate order of importance.
Cigarette smoking
In smokers, the risk of developing PAD is increased twofold to threefold, and smoking corre-
lates more closely with development of intermittent claudication than any other cardiovascular
risk factor." Patients with PAD who continue to smoke have a greater likelihood ofvascular dis-
ease progression, MI, stroke, and death than those who stop smoking. 8,9 Smoking is also closely
associated with the risk of limb loss.U' Based on these findings, smoking cessation is a critical
step in the management of LC, even though the effect on the claudication symptoms may not
be immediately evident.'! In a self-selected parallel group study, there was significant difference
in the change in ankle pressure and treadmill walking distance between those patients who con-
tinued to smoke and those who sropped.l-
Recommendation 22: Smoking cessation in peripheral arterial disease
All patients with peripheral arterial disease should be strongly and repeatedly advised to
stop smoking. Cessation rates are likely to be enhanced by a special program.
Obesity
The weight of the patient may be directly related to claudication distance. Overweight patients
with IC therefore directly benefit from reducing weight in terms of claudication distance. In
addition, obesity is a recognized risk factor of most fatal and nonfatal cardiovascular events.
Diabetes mellitus
Diabetes mellitus is highly associated with lower-extremity arterial disease and its progres-
sion.l 3,14,15,16 Although glycemic control correlates well with an improvement in most diabetic
complications, there is contlicting evidence about a direct correlation between glycemic control
and the severity or progression ofPAD.15,17,18,19,20 The United Kingdom Prospective Diabetes
Study (UKPDS) provides new information on intensive glycemic control in terms of both large-
vessel and small-vessel end points. 21,22 Intensive glycemic control provided a significant reduction
in any diabetes end point (largely microvascular) and MI. Use of metformin was also associated
with a reduction in diabetes end points, all-cause mortality, and MI. However, neither intensive
treatment reduced the risk of PAD. Thus, intensive glycemic control alone is insufficient to pre-
vent the peripheral vascular complications of diabetes and underlines the importance of the con-
trol of other risk factors (smoking, hypertension, and hyperlipidemia) in these patients.
Recommendation 23: Control of diabetes in peripheral arterial disease
Patients with diabetes and peripheral arterial disease should have aggressive control and
normalization of blood sugar. Fasting blood sugars should range from 80 to 120 mg/dL,
and postprandial sugars should be <180 mg/dL; hemoglobin Alc should be <7.0%.
Diabetic patients are at particular risk of developing ulcers on their feet because of preexisting
diabetic sensory neuropathy. Foot deformity caused by a motor neuropathy will also predispose
to ulceration. It is therefore important to educate diabetic patients and their family about the
importance of examining the feet regularly, wearing protective footwear at all times, avoiding
abnormal pressure, and visiting a specialized diabetic foot clinic if they have any concerns.
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Recommendation 24: Diabetic foot care in peripheral arterial disease
All diabetic patients with peripheral arterial disease should receive special advice and
regular supervision to minimize the risks of developing diabetic foot complications.
Hyperlipidemia
In PAD, the major lipid risk factors for peripheral atherosclerosis are elevated LDL cholesterol
and triglyceride levels and low HDL cholestcrollevelsy,ls,23,24,25 Lp(a) is a lipoprotein fraction
that is an independent risk factor for PAD.26 Unfortunately, there are no specific treatments for
elevated Lp( a) levels except to aggressively treat abnormalities in other lipid fractions. Recent
trials support the observation that lipid modification is associated with stabilization or regression
of femoral atherosclerosis.27,28,29,30,31 However, this was not reproduced in the Probucol trial,
in which treatment did not change the severity of femoral atherosclerosis but prevented progres-
sion. 32 Neither was this reproduced in the KAPS study, in which pravastatin had no effect on
the femoral artery but did reduce plaques in the carotid.33 Lipid modification in patients with
CAD is associated with a reduction in the risk of vascular death. For example, simvastatin
reduced cardiovascular events significantly.34 The effect of lipid-lowering therapy on the clinical
progression of PAD was evaluated in a subgroup analysis of the Scandinavian simvastatin (45)
smdy.35 In this study, simvastatin was associated with a 38% risk reduction in the development
or worsening of claudication.
Current National Cholesterol Education Program (NCEP) recommendations are to obtain a
screening lipid profile in all patients with PAD.36 For patients with PAD who have elevated
lipids, dietary restrictions should be the first advice.I? This may be effective in treating hyper-
triglyceridemia, which contributes to progression of the disease.9 The treatment goals are to
achieve an LDL cholesterol less than 100 mg/dL (2.6 mmoljL), which will usually require tile
use of drug treatment. In addition, patients with a low HDL cholesterol level should be consid-
ered for niacin therapy. Patients with low HDL and elevated triglyceride levels in whom diet
therapy fails should be placed on fibrates. On the basis of reponed trials, tile use of statins
would result in avoiding one death per year in 640 patients treated.38 Additional studies in the
PAD population are needed to assess the effects of lipid lowering on cardiovascular mortality
and progression ofleg arterial disease (see also B 5.1.4, Cost-effectiveness of Lipid Control in
Intermittent Claudication, p S125). .
Recommendation 25: Lipid control in peripheral arterial disease
Because of the high incidence of coexistent coronary disease and similar mortality risk
to coronary patients, patients with peripheral arterial disease with a Iow-density
lipoprotein (LDL) cholesterol level greater than 125 mgjdL should be placed on
therapy. In the first instance, a diet should be tried. If this fails to achieve a goal of
LDL cholesterol level less than 100 mgjdL, then medications should be tried.
Hypertension
The effects of the treatment of hypertension on the natural history of peripheral atherosclerosis
have not been evaluated. In the claudicant, tile goal of hypertension therapy is to reduce the risk
of stroke, MI, and cardiovascular death, and this risk factor should be controlled according to
tile INC guidelines.82 However, clinicians should be aware that when drug therapy results in a
large decrease in systemic blood pressure, some patients may experience a slight worsening of
their claudication symptoms.s? Nevertheless, it is important that such patients understand the
more important risk to their life from uncontrolled hypertension, albeit asymptomatic, than
from claudication. It also should be remembered that hypertension can be secondary to renal
artery disease, and this is particularly likely in patients with PAD. The plasma creatinine level
should therefore be monitored particularly carefully. The drug treatment of hypertension can
follow the same guidelines as in patients without PAD. There is no good evidence that beta
blockers adversely affect mild to moderate claudication.w
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Recommendation 26: Control of hypertension in peripheral arterial disease
Peripheral arterial disease patients with hypertension should have this risk factor con-
trolled according to Joint National Committee (VI) (JNC [VI]) guidelines.
Hypercoagulable states
Hypercoagulable states should be detected and treated where needed (see Recommendation 14, p
565 and Table 13, p 564). The only available treatment for these conditions is oral anticoagulation.
Recommendation 27: Hypercoagulable states in intermittent claudication
Patients with intermittent claudication who have a hypercoagulable state and proven
arterial or venous thrombosis should be anticoagulated with coumarins.
Homocysteine
Recently, several reports have shown a strong association between increases in plasma homocys-
teine concentration and PAD.4! This may be an important risk factor in patients younger than
50 years who present with claudication. A meta-analysis has clarified that at least the risk of
CAD is increased with a homocysteine level above 5 mmol/L.42 In patients with CAD, elevated
homocysteine levels are also independent predictors of deatll.43 Therapy with folic acid, vitamin
Bl2 , and vitamin B6 is effective in lowering homocysteine levels, but the effects on vascular dis-
ease severity have not been evaluated.
Critical Issue 7: Hyperhomocysteinemia in peripheral arterial disease
There is a need for therapeutic trials to define the role of vitamin supplementation in
preventing peripheral arterial disease progression and cardiovascular death. Currently
there is no solid evidence to support the treatment of an elevated homocysteine level
unless the symptomatic patient is known to have folic acid or vitamin B12 deficiency.
Hormone replacement therapy
The potential benefits of estrogen plus progesterone therapy in preventing cardiovascular events
in women with a history of CAD have been reported.H
Antiplatelet therapy
The Antiplatelct Trialists Collaboration reviewed 189 controlled studies involving secondary pre-
vention of cardiovascular events in over 100,000 patients with cardiovascular symptoms. Overall,
there was a 25% decrease in fatal and nonfatal MI, stroke, and vascular death. Fewer than 4,000
patients with PAD were entered (in 28 studies). They showed identical benefit to the overall
group, but, because of the low numbers, this was not statistically significant.sf The benefit per-
sisted for at least 3 years and was similar for aspirin, at dosages ranging from 75 to 350 mgy'd. In
the Physician rs Health Study, low doses of aspirin resulted in a 54% reduction in the risk of
peripheral arterial surgery as compared with placebo.tv It should be noted that higher doses of
aspirin (greater than 325 mg daily) are often associated with gastrointestinal intclerance.V
Ticlopidine has been shown to reduce the risk of stroke and fatal and nonfatal MI by 29% com-
pared with placebo.sf The most recently studied antiplatelet agent in PAD is clopidogrel, which,
like ticlopidine, blocks the activation of platelets by ADP. In 19,185 study subjects enrolled with
cardiovascular disease, 6,452 patients had PAD. All patients were randomized to low-dose
aspirin or clopidogrel and followed up for an average of 1 to 3 years. In the PAD subgroup,
clopidogrel (as compared with aspirin) resulted in a 23.8% relative risk reduction of ischemic
stroke, MI, or vascular death, although tile 95% confidence interval was wide (8.9%-36%), and
this included not only patients with IC but also those following revascularization.t? Additional
studies will be necessary to define the role of these new potent (but more expensive) antiplatelet
agents in the overall management of PAD 50 (see also B 5.1.3, The Cost-effectiveness of
Antiplatclcr Therapy in Intermittent Claudication, P 5125).
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Reconunendation 28: Antiplatelet therapy in peripheral arterial disease
All patients with peripheral arterial disease (whether symptomatic or asymptomatic)
should be considered for treatment with low-dose aspirin, or other approved
antiplatelet (unless contraindicated), to reduce the risk of cardiovascular morbidity and
mortality.
The preceding discussion of measures to modify risk factors, including anti-platelet therapy, directed
at altel'irl-lJ natural history and reducing systemic risk ispresented in algorithm form in B 4.1.3}
page 86.
Exercise rehabilitation
In patients with claudication, convincing data indicate that an exercise program can produce clinically
significant improvements in exercise performance and community-based walking ability. However,
exercise can range from the physician recommending unsupervised walking in the community to a
formal supervised exercise program on a treadmill. Severalstudies suggest that some level of supervi-
sion is necessary to achieve optimal results.51,52,53 In prospective studies ofsupervised exercise con-
ducted for 3 months or longer, there are clear increasesin treadmill exercise performance, and a less-
ening of claudication pain severityduring exercise.54,55,56,57,58,59,60,61,62,63,M ,65,66
A recently published meta-analysis of these studies showed an average 179% increase in initial
claudication distance and a 122% increase in maximal walking distance on the treadmill.67 This
meta-analysis included uncontrolled observational studies as well. Table 15 summarizes the
results obtained in controlled trials. The predictors of response to the training program include
a high level of claudication pain during the training sessions and 6 months or longer of formal
training and walking exercise (vs other training modalities). Treadmill exercise also has been
shown to be more effective than strength training or combinations of training modalities.55
Finally, there is virtually no morbidity or mortality from exercise rehabilitation. 68 Several studies
also have shown improvements in peak exercise performance and peak oxygen consumption
with treadmill training. These changes are important because, as a result, patients are able to
perform activities of higher intensities such as climbing stairs, gardening. and dancing, activities
that were not possible before training. These studies also have shown that, at a given subrnaxi-
mal workload, exercise training decreased heart rate, ventilation, and oxygen consumption. 54 ,55
These changes may contribute to the ability to sustain walking exercise for longer times before
claudication pain limits the activity.
In addition to evaluating changes in treadmill exercise performance, some studies used patient-
based outcome assessment, SF-36 or WIQ, to determine changes in functional status and quali-
ty of lite with exercise. This is important because the patient with claudication is seeking treat-
ment for a disabling symptom that affects his or her daily activities.Z'' Using this approach,
supervised training has been shown to improve the ability of the claudicant to walk longer dis-
tances at faster speeds, with less severe claudication pain.54 ,71 These studies also showed
improved total caloric expenditure and physical functioning using a variety of validated ques-
tionnaires. Thus, a comprehensive approach needs to be used to assess the benefits of any clau-
dication therapy.
Exercise rehabilitation also has the potential to favorably modify other cardiovascular risk fac-
tors. Although not studied in a comprehensive fashion, initial studies have shown an improve-
ment in glucose metabolism, a reduction in cholesterol and triglyceride concentrations (when
diet therapy was also used), and enhanced smoking cessation.72.73 Improvements in these car-
diovascular risk factors are not typically seen with drug therapy for claudication or with bypass
surgery or angioplasry, An important issue is patient acceptability and compliance with exercise
training. Many patients may have contraindications for exercise (eg, severe CAD, musculoskele-
Joua.'IAL OF VASCUlAR SURGERY
884 B4 Treatment of Intermittent Claudication January 2000
Table 15: Randomized, controlled trials evaluating the efficacy of exercise rehabilitation
Duration Change in Functional
Group n Intervention (mo) ACD (%) assessment
Larsen & Lassen,62 1966 T 7 Daily walks 6 183"t No
C 7 Placebo tablet -6
Holm et al,77 1973 T 6 Exercise 4 133"t No
C 6 Placebo tablet NC
Dahllofer al,61 1974 T 11 Exercise 6 117"t No
C 23 Placebo tablet NC
Dahllof et al,60 1976 T 8 Exercise 4 13s"t No
C 10 Placebo tablet 75"
Lundgrencf 1989 Tl 25 Surgery + exercise 6 263*t No
T2 25 Surgery 173*t
T3 25 Exercise Is1"t
Creasy et al,58 1990 Tl 13 Exercise 6 44l*t No
T2 20 Angioplasty 57
Hiatt et al,54 1990 T 9 Supervised exercise 3 123*t Improved
C 10 Control 20* NC
Mannarino er al,66 1991 Tl 10 Exercise + antiplatelet 6 105"t No
T2 10 Exercise 86"t
T3 10 Antiplatelct 3S"
Hiatt et al,55 1994 Tl 9 Supervised exercise 3 74*t Improved
T2 8 Strength training 36* NC
C 10 Control -1 NC
Regensteiner et al,53 1997 Tl 10 Supervised exercise 3 137"t Improved
T2 10 Home exercise 5 NC
Patterson et al,69 1997 Tl 19 Supervised exercise 6 19s*t Improved
T2 19 Home exercise 83* Improved
Abbreviations: T, treated group; C, control group; Functional assessment, use of questionnaire to evaluate community-based function-
al status; NC, no change.
"1' -c 0.05 compared with baseline.
[p -e 0.05 difference between groups. For the Creasy study, the data given are for the 12-month follow-up point.
tal limitations, or neurological impairments). Other patients may be unwilling to participate in
supervised sessions if they have long distances to travel, if an appropriate rehabilitation program
is not available in their area, or if the expenses incurred are too great. In a German study of 201
patients recommended tor exercise, it was found that 34% had contraindications, and 36% of the
remaining patients refused to participate because of these same arguments.Zs However, an
American study showed that only 9% of patients referred for supervised exercise training were
excluded on screening for the program.P'' These exclusions were all tor severe cardiac ischemia
on the initial treadmill test. In patients enrolled, 73% were able to complete the program with-
out difficulty. Thus, when offered, most patients are able to enroll and successfully complete a
training program for their claudication.
An important aspect of exercise is that patients need more than the simple recommendation by
the physician to engage in walking exercise at home. In one study, patients with Ie were ran-
domized to a 3-month program of supervised exercise or home-based exercise. Patients exercis-
ing at home were given detailed instructions by a rehabilitation nurse at the start of the pro-
gram. They were also contacted weekly by phone to assess compliance and provide encourage-
ment. Whereas the supervised patients had the expected improvements in treadmill exercise
performance and quality of life, those patients trained at home realized no benefit.53 Thus, exer-
cise is effective primarily when performed in a supervised environment. However, unsupervised
training may be more effective than no training at all.
The exercise prescription
Exercise sessions are typically held 3 times a week for approximately 1 hour each, and 3- to 6-
month periods of training are customary. During the exercise sessions, rest periods (induced by
claudication) are interspersed with bouts of treadmill walking. The patient walks on the tread-
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mill until a mild or moderate level of pain is reached (scored as "3" or "4" on a 1-5 scale as
previously described). At that point, the patient rests until the pain abates. The initial training
workload is determined from the symptom-limited maximal treadmill test on entry, such that
the intensity of the treadmill exercise is set to the workload that initially brings on claudication
pain in the patient. In subsequent visits, the speed or grade is increased if the patient is able to
walk for 10 minutes or longer at the lower workload without reaching moderate claudication
pain. Either speed or grade can be increased, but an increased grade is recommended ifthe
patient can already walk at 2 mph (3.2 kmy'h). An additional goal of the program is to increase
patient walking speed up to the normal 3.0 mph (4.8 km/h) from the average PAD patient
walking speed of 1.5 to 2.0 mph (approximately 2.4-3.2 kmyh).
The precise mechanism behind improvement of walking ability with exercise is not established.
Collateral development seems unlikely because ankle pressures and limb flow do not show any
impressive increases after exercise.75,76 Even though some improvement in hemodynamic para-
meters are shown, they are poorly correlated to an increased walking capacity. 54 Other possible
explanations might be an improved metabolic capacity in the muscles and altered gait using
more proximal nonischemic muscle, by analogy to amputees walking with a prosthesis.61,77,78 A
further question is whether pain-developing exercise has any negative impact. It has been shown
that patients with IC have an increased microalbuminuria after exercise, supporting the interpre-
tation that an ischemia reperfusion injury takes piace.Z? This is also supported by the findings of
thromboxane and neutrophil changes in claudicants during and after walking.80 By contrast, a
recent study showed that treadmill exercise is not associated with a change in any plasma marker
of endothelial damage.s!
Summary: Exercise training
Numerous trials provide evidence that the walking capacity and overall functional status are
increased by exercise training in patients with disabling claudication. The most effective pro-
grams are supervised, employ walking exercise, and last 3 to 6 months. Maintenance of regular
exercise, whether supervised or not, needs to be continued indefinitely or the benefit will even"
tually be lost.
Recommendation 29: Exercise training in intermittent claudication
A program of exercise therapy (preferably supervised) should always be considered as
part of the initial treatment for patients with intermittent claudication.
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B 4.2 Pharmacotherapy for Symptoms of Intermittent Claudication
B 4.2.1 Introduction
Patients with intermittent claudication mostly receive drug treatment for coexisting disease (eg,
hypertension), risk factor modification (eg, hyperlipidemia), and as prophylaxis against throm-
botic events associated with atherosclerosis (eg, antiplatclet drugs). No pharmacological agent
has proved efficacious enough in providing significant reduction or elimination of symptoms of
claudication to gain widespread acceptance and use for improving walking. However, a number
of types of drugs have been promoted for this indication, with varying evidential support, and
these will be considered in this section. These drugs are frequently grouped together under the
heading "vasoactive agents," partly because of their multiplicity of potential mechanisms of
action. Some of the drugs have been distinguished as "rheologic agents," but tor others such
as prostanoids, the mode of action is still not well delineated. These drugs should not replace
exercise programs and other lifestyle adjustments described in B 4.1.2, Basic Treatment (p
S80). However, they have a place as adjunctive treatment where invasive therapy is not indicat-
ed, in those who cannot or will not follow exercise therapy or in those who have not sufficient-
ly benefited from it (see D 4.13.5, Adjuvant Therapy, p 5250). Table 16 and Figure 20 show
results of randomized, placebo-controlled, double-blind trials of pharmacotherapy in Ie.
B 4.2.2 Established Drugs With Proven but Small Benefit in Improving Claudication
Pentoxifylline
Pentoxifylline improves red cell deforrnability, lowers fibrinogen levels, decreases platelet aggre-
gation, and has been shown to increase walking distance in patients with PAD. In early con-
trolled trials, the drug produced a 22% improvement over placebo in leD and a 12%improve-
ment in the ACD.l However, these percent improvements wen; expressed as the mean differ-
ence between week 2 and week 24. The actual improvement over placebo from entry to 6
months in ACD was 18%, but this difference was not statistically significant. A more recent
